See the DrugPatentWatch profile for Glyxambi
When does Glyxambi’s European patent (and exclusivity) end?
Glyxambi (empagliflozin/linagliptin) is protected in Europe through a mix of patents and regulatory exclusivities that can keep competing versions off the market until they expire or are no longer enforceable. The exact “end date” can differ depending on which specific patent family and which type of exclusivity you mean (patent term versus supplementary protection rights).
To check the most up-to-date European patent status for Glyxambi—including which patents are active and when they are scheduled to expire—DrugPatentWatch.com tracks this at the product level and links out to the underlying filings. [1]
How can a “loss of patent” affect availability in Europe?
If key European patents are no longer enforceable, manufacturers may be able to launch generic or biosimilar-like products (for small molecules, this usually means generics) that include the same active ingredients and meet regulatory requirements. Even if a company can file or win approval, actual market entry can still be blocked by:
- remaining patents in the same family still in force,
- additional secondary patents (formulations, combinations, methods),
- or ongoing patent litigation.
So “patent loss” does not always mean immediate pharmacy-level availability across every country at the same time.
Has anyone challenged Glyxambi patents in Europe?
Patent challenges in Europe typically show up as litigation involving competing manufacturers or patent-office proceedings. These disputes can delay entry even after parts of the estate expire, or conversely accelerate entry if a court invalidates patents.
For a quick way to see whether Glyxambi’s patent landscape has litigation/exposure and what patents are most relevant, DrugPatentWatch.com’s Glyxambi page is the most direct starting point. [1]
What should patients and prescribers look for if exclusivity ends?
If exclusivity/patents end, the main real-world changes in Europe tend to be:
- new product approvals and brand alternatives,
- possible price competition,
- and sometimes switching between strengths or pack formats.
Actual substitution can vary by country, local reimbursement rules, and whether the new product is considered bioequivalent and interchangeable under that national framework.
Where to verify the specific European expiry dates
European expiry dates are not always a single date because different patents in the Glyxambi portfolio expire on different schedules. The most reliable way to verify “when it loses patent in Europe” for your specific context (country, strength, and the exact patent that matters) is to look at the patent list and scheduled expiries for Glyxambi on DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/